Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size is valued at USD 5.4 Bn in 2023 and is predicted to reach USD 10.8 Bn by the year 2031 at a 9.3% CAGR during the forecast period for 2024-2031
Both liposomal and lipid nanoparticle systems are notable advancements in drug delivery technology, specifically for delivering therapeutic compounds that are challenging to administer due to stability or toxicity concerns. Their progress is constantly advancing as they tackle the difficulties of accurately focusing on and treating different ailments, particularly in the realm of personalized medicine and advanced medicines.
The enormous need for medicine on a global scale necessitates the consumption of pharmaceutical lipids, particularly liposomal medicines utilized in cancer treatment. Furthermore, the need for nanomedicine is rising because of the older population and the rise in chronic disorders. This is because nanoparticles have special properties like improved permeability and prolonged circulation, making them ideal for treating complex chronic ailments.
Nevertheless, the market expansion of the pharmaceutical industry's liposomal and lipid nanoparticle delivery system sales is hindered by stringent regulatory standards concerning safety and health. Additionally, the product's effectiveness in preventing fog in environments with significant temperature changes or high nanoparticle contract manufacturing is limited. These regulations have been implemented to ensure the quality and efficacy of medications due to the global expansion of the pharmaceutical industry.
In several nations, regulatory agencies have arisen to fulfill the legal needs of drug research. Furthermore, the inflow of R&D capital for creating and commercializing complicated pharmaceuticals via nanoparticle contract manufacturing was constrained by tight rules enacted by multiple governments. Due to the COVID-19 pandemic, which has affected the overall world market and forced the closure of number of factories to protect their personnel from contracting the virus, the expansion of the industry may be hindered.
Competitive Landscape
Some Major Key Players In The Liposomal and Lipid Nanoparticle Drug Delivery Systems Market:
- Johnson & Johnson
- Sun Pharmaceutical
- CSPC
- Teva
- Fudan-Zhangjiang
- Zydus Cadila
- TTY Biopharma
- Pacira
- Luye Pharma
- Leadiant Biosciences
- Ipsen
- Sayre Therapeutics
- Alnylam
- Bausch Health
- Acrotech Biopharma
- Takeda
- Chiesi Farmaceutici
- Gilead Sciences
- Other Market Players
Market Segmentation
The global market of liposomal and lipid nanoparticle drug delivery systems is categorized into type and end-user. As per the type segment, the market is segmented into liposome drugs and lipid nanoparticle drugs. By application, the market comprises hospitals, retail pharmacies, and Others.
Based On The Type, The Lipid Nanoparticles Segment Is Accounted As A Major Contributor To The Market.
The lipid nanoparticles liposomal and lipid nanoparticle drug delivery systems market is expected to hold a major global market share in 2023. Lipid nanoparticles are the most common type in the nanoparticle contract manufacturing industry because of their unique characteristics and wide range of uses. They are versatile enough to be used in various industries, the most notable being healthcare.
Hospital Segment To Witness Growth At A Rapid Rate.
Hospitals dominates the segment because hospitals have saved countless lives. People with serious illnesses, such as cancer, neurological disorders, or catastrophic injuries, would benefit greatly from being there. Unfortunately, certain diseases do not have a cure. As a means of sustaining human life, hospitals have state-of-the-art facilities and technologies, especially in countries like the US, Germany, the U.K., China, and India.
In The Region, The North American Liposomal And Lipid Nanoparticle Drug Delivery Systems Market Holds A Significant Revenue Share.
The North American liposomal and lipid nanoparticle drug delivery systems market is expected to register the highest revenue share in the near future. This can be attributed to the rapid development of technology in underdeveloped regions. In addition, Europe is predicted to grow rapidly in the global market of liposomal and lipid nanoparticle drug delivery systems because of significant progress in materials science and nanotechnology. Innovation brought about by these breakthroughs has spurred nanoparticle manufacturing processes.
Recent Developments:
- In Dec 2021, Sun Pharmaceuticals Industries announced that one of its fully-owned subsidiaries has obtained final approval from the US FDA for its ANDA (Abbreviated New Drug Application) for a generic version of Amphotericin B Liposome for Injection, with a strength of 50 mg/vial in a single-dose vial. The approval of the generic product is contingent upon the reference product, AmBisome Liposome for Injection, 50 mg/vial.
- In March 2021, Genevant Sciences and Takeda Pharmaceutical Company Limited ("Takeda") have entered into a global collaboration and license agreement for the development, marketing, and discovery of LNP-delivered nucleic acid therapeutics that target drug targets in hepatic stellate cells that were previously inaccessible. The therapeutics are intended to be used to treat liver fibrosis.
Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 5.4 Bn |
|
Revenue Forecast In 2031 |
USD 10.8 Bn |
|
Growth Rate CAGR |
CAGR of 9.37% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type and Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Johnson & Johnson, Sun Pharmaceutical, CSPC, Teva, Fudan-Zhangjiang, Zydus Cadila (India), TTY Biopharma, Pacira, Luye Pharma, Leadiant Biosciences, Ipsen (France), Sayre Therapeutics, Alnylam, Bausch Health, Acrotech Biopharma, Takeda, Chiesi Farmaceutici, and Gilead Sciences. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
